Specialized yoga program means better sleep for some cancer survivors

Researchers at the University of Rochester have posted an abstract of a phase II/III trial to determine whether a yoga program specifically designed for cancer survivors could help solve some sleep problems among patients recovering from cancer treatment.

COHORT

410 survivors of early stage cancer, predominantly female (96%) and largely breast cancer (75%) who reported some sleep problems in the months (between 2 and 24) following adjuvant cancer therapy.

Patients were randomized into two groups, 1) one group received standard care monitoring, 2) the other group received a four-week yoga program (biweekly 75-minute sessions)

CONCLUSIONS

At the end of the trial, twice as many patients in the yoga program reported having overcome their impaired sleep issues (as measured on the Pittsburgh Sleep Quality Index) than in the control group.

There was also a considerable drop among yoga participants' use of sleeping pills, while their use among the other group went up. Furthermore, the yoga group experienced less daytime sleepiness, which no doubt contributed to their ability to sleep at night.

The yoga program used in this study was designed specifically for cancer survivors, known as UR Yoga for Cancer Survivors or YOCAS®. It is low-impact, featuring visualization, meditation, breathing exercises, and some gentle postures in standing, seated, transitional, and lying-down positions.

PUBLICATIONS

These results were presented in a press conference for the upcoming 2010 ASCO Annual Meeting; they have not been published in a peer-reviewed journal yet and until then should be considered preliminary only.

By Ross Bonander

Sourced from a variety of news outlets

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap